152 related articles for article (PubMed ID: 23331028)
1. Novel s-nitrosothiols have potential therapeutic uses for cystic fibrosis.
Zaman K; Fraser-Butler M; Bennett D
Curr Pharm Des; 2013; 19(19):3509-20. PubMed ID: 23331028
[TBL] [Abstract][Full Text] [Related]
2. Novel Approaches for Potential Therapy of Cystic Fibrosis.
Sawczak V; Getsy P; Zaidi A; Sun F; Zaman K; Gaston B
Curr Drug Targets; 2015; 16(9):923-36. PubMed ID: 25557257
[TBL] [Abstract][Full Text] [Related]
3. S-Nitrosothiols increases cystic fibrosis transmembrane regulator expression and maturation in the cell surface.
Zaman K; Bennett D; Fraser-Butler M; Greenberg Z; Getsy P; Sattar A; Smith L; Corey D; Sun F; Hunt J; Lewis SJ; Gaston B
Biochem Biophys Res Commun; 2014 Jan; 443(4):1257-62. PubMed ID: 24393850
[TBL] [Abstract][Full Text] [Related]
4. S-nitrosothiols signaling in cystic fibrosis airways.
Liu M; Zaman R; Sawczak V; Periasamy A; Sun F; Zaman K
J Biosci; 2021; 46():. PubMed ID: 34857676
[TBL] [Abstract][Full Text] [Related]
5.
Zaman K; Knight J; Hussain F; Cao R; Estabrooks SK; Altawallbeh G; Holloway K; Jafri A; Sawczak V; Li Y; Getsy P; Sun F; Raffay T; Cotton C; Brodsky JL; Periasamy A; Lewis SJ; Gaston B
Am J Respir Cell Mol Biol; 2019 Dec; 61(6):765-775. PubMed ID: 31596601
[No Abstract] [Full Text] [Related]
6. S-nitrosylating agents: a novel class of compounds that increase cystic fibrosis transmembrane conductance regulator expression and maturation in epithelial cells.
Zaman K; Carraro S; Doherty J; Henderson EM; Lendermon E; Liu L; Verghese G; Zigler M; Ross M; Park E; Palmer LA; Doctor A; Stamler JS; Gaston B
Mol Pharmacol; 2006 Oct; 70(4):1435-42. PubMed ID: 16857740
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of CFTR maturation by S-nitrosoglutathione reductase.
Zaman K; Sawczak V; Zaidi A; Butler M; Bennett D; Getsy P; Zeinomar M; Greenberg Z; Forbes M; Rehman S; Jyothikumar V; DeRonde K; Sattar A; Smith L; Corey D; Straub A; Sun F; Palmer L; Periasamy A; Randell S; Kelley TJ; Lewis SJ; Gaston B
Am J Physiol Lung Cell Mol Physiol; 2016 Feb; 310(3):L263-70. PubMed ID: 26637637
[TBL] [Abstract][Full Text] [Related]
8. S-nitrosoglutathione increases cystic fibrosis transmembrane regulator maturation.
Zaman K; McPherson M; Vaughan J; Hunt J; Mendes F; Gaston B; Palmer LA
Biochem Biophys Res Commun; 2001 Jun; 284(1):65-70. PubMed ID: 11374871
[TBL] [Abstract][Full Text] [Related]
9. ERp29 regulates DeltaF508 and wild-type cystic fibrosis transmembrane conductance regulator (CFTR) trafficking to the plasma membrane in cystic fibrosis (CF) and non-CF epithelial cells.
Suaud L; Miller K; Alvey L; Yan W; Robay A; Kebler C; Kreindler JL; Guttentag S; Hubbard MJ; Rubenstein RC
J Biol Chem; 2011 Jun; 286(24):21239-53. PubMed ID: 21525008
[TBL] [Abstract][Full Text] [Related]
10. Is it go or NO go for S-nitrosylation modification-based therapies of cystic fibrosis transmembrane regulator trafficking?
Zeitlin PL
Mol Pharmacol; 2006 Oct; 70(4):1155-8. PubMed ID: 16877677
[TBL] [Abstract][Full Text] [Related]
11. Hsp 70/Hsp 90 organizing protein as a nitrosylation target in cystic fibrosis therapy.
Marozkina NV; Yemen S; Borowitz M; Liu L; Plapp M; Sun F; Islam R; Erdmann-Gilmore P; Townsend RR; Lichti CF; Mantri S; Clapp PW; Randell SH; Gaston B; Zaman K
Proc Natl Acad Sci U S A; 2010 Jun; 107(25):11393-8. PubMed ID: 20534503
[TBL] [Abstract][Full Text] [Related]
12. Rescuing mutant CFTR: a multi-task approach to a better outcome in treating cystic fibrosis.
Amaral MD; Farinha CM
Curr Pharm Des; 2013; 19(19):3497-508. PubMed ID: 23331027
[TBL] [Abstract][Full Text] [Related]
13. The HDAC inhibitor SAHA does not rescue CFTR membrane expression in Cystic Fibrosis.
Bergougnoux A; Petit A; Knabe L; Bribes E; Chiron R; De Sario A; Claustres M; Molinari N; Vachier I; Taulan-Cadars M; Bourdin A
Int J Biochem Cell Biol; 2017 Jul; 88():124-132. PubMed ID: 28478266
[TBL] [Abstract][Full Text] [Related]
14. Cystic fibrosis: CFTR modulators and their mechanism of action.
Nieddu E
Curr Pharm Des; 2013; 19(19):3474-5. PubMed ID: 23331031
[No Abstract] [Full Text] [Related]
15. Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Chung WJ; Goeckeler-Fried JL; Havasi V; Chiang A; Rowe SM; Plyler ZE; Hong JS; Mazur M; Piazza GA; Keeton AB; White EL; Rasmussen L; Weissman AM; Denny RA; Brodsky JL; Sorscher EJ
PLoS One; 2016; 11(10):e0163615. PubMed ID: 27732613
[TBL] [Abstract][Full Text] [Related]
16. Functional cystic fibrosis transmembrane conductance regulator tagged with an epitope of the vesicular stomatis virus glycoprotein can be addressed to the apical domain of polarized cells.
Costa de Beauregard MA; Edelman A; Chesnoy-Marchais D; Tondelier D; Lapillonne A; El Marjou F; Robine S; Louvard D
Eur J Cell Biol; 2000 Nov; 79(11):795-802. PubMed ID: 11139142
[TBL] [Abstract][Full Text] [Related]
17. Syntaxin 8 and the Endoplasmic Reticulum Processing of ΔF508-CFTR.
Sabirzhanova I; Boinot C; Guggino WB; Cebotaru L
Cell Physiol Biochem; 2018; 51(3):1489-1499. PubMed ID: 30485852
[TBL] [Abstract][Full Text] [Related]
18. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
Birault V; Solari R; Hanrahan J; Thomas DY
Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
[TBL] [Abstract][Full Text] [Related]
19. Protein processing and inflammatory signaling in Cystic Fibrosis: challenges and therapeutic strategies.
Belcher CN; Vij N
Curr Mol Med; 2010 Feb; 10(1):82-94. PubMed ID: 20205681
[TBL] [Abstract][Full Text] [Related]
20. CFTR and chaperones: processing and degradation.
Amaral MD
J Mol Neurosci; 2004; 23(1-2):41-8. PubMed ID: 15126691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
